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Abstract Botulinum neurotoxin is the therapy of choice
for all forms of cervical dystonia (CD), but treatment
regimens still vary considerably. The interpretation of
treatment outcome is mainly based on the clinical experi-
ence and on the scientific value of the rating scales applied.
The aim of this review is to describe the historical devel-
opment of rating scales for the assessment of CD and to
provide an appraisal of their advantages and drawbacks.
The Tsui score and the Toronto Western Spasmodic Tor-
ticollis Rating Scale (TWSTRS) have been widely
employed in numerous clinical studies as specific instru-
ments for CD. The obvious advantage of the Tsui score is
its simplicity so that it can be easily implemented in clin-
ical routine. The TWSTRS allows a more sophisticated
assessment of functional features of CD, but only the Tsui
score includes a rating for tremor. Other benefits of the
TWSTRS are the disability and pain subscales, but despite
its value in clinical trials, it might be too complex for
routine clinical practice. None of the rating scales used at
present has been rigorously tested for responsiveness to
detect significant changes in clinical status after therapeutic
interventions. Moreover, clinical data support a new clas-
sification of CD leading to a differentiation between head
and neck subtypes. As the current rating scales are not able
to cover all these aspects of the disorder, further research is
needed to develop a valid and reliable instrument which
considers the most current classification of CD.
Keywords Cervical dystonia  Rating scales 
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Introduction
Idiopathic cervical dystonia (CD) is the most frequent form
of focal dystonia encountered in neurological practice. CD
is characterized by involuntary contractions of specific
muscles leading to abnormal movements of the head and/or
unintentional adoption of sustained and frequently painful
postures of the head, neck and shoulders. Botulinum neu-
rotoxin (BoNT) has become the established treatment of
choice, and the American Academy of Neurology (AAN)
issued a level A recommendation (Simpson et al. 2008).
About 80 short-term and long-term studies in CD patients
have been published (Kamm and Benecke 2011; Costa
et al. 2005a, b, c; Truong and Jost 2006) applying a variety
of objective and subjective rating scales to evaluate the
outcome of treatment with BoNT.
Differential diagnosis and treatment of CD are mainly
based on the clinical assessment. Diagnostic aids such as
computer tomographic scans or magnetic resonance imag-
ing can provide some additional information in specific
cases. However, in routine practice, determination of dif-
ferent subtypes of CD and BoNT injection of the affected
muscles depends on the diagnostic skills of the treating
physician. Furthermore, there are no objective functional
parameters for CD such as blood pressure in hypertension or
lung function in asthma patients which can be precisely
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measured using manual or electronic devices. This
emphasizes the need for reliable rating scales that cover the
most important aspects of different subtypes of CD.
An ideal rating scale should be as short and simple as
possible in order to be implemented across multicenter
clinical studies as well as in daily clinical practice. Each
item of the scale has to be clearly defined to guarantee a
high inter-rater reliability. Applying a rating scale, the
assessor should be able to discriminate between subtypes of
CD and to quantify the effect after administration of
treatment. In addition, rating scale for CD should cover
those aspects which are most important to patients. Not
only functional disability but also the influence on activi-
ties of daily living and the psychosocial burden imposed on
patient’s well-being need to be considered.
Precise tools to rate improvement or deterioration are
important for any disorder to assess the patient’s disease
state as well as the outcome after treatment. The aim of this
review is to describe historical and current rating scales
used to evaluate CD and to provide a critical assessment
taking into account the classification of different CD sub-
types and dystonic tremor.
Rating scales for CD
Several different rating scales have been proposed to
evaluate CD. The Fahn–Marsden dystonia scale has been
developed for the assessment of generalized dystonia,
originally for use in a therapeutic trial of trihexyphenidyl
(Burke et al. 1985). The scale rates the severity of move-
ments affecting different body parts, each on a 5-point
scale, but it includes only one item of CD (i.e. neck). The
Fahn–Marsden scale also takes into account provoking
factors: 1 (dystonia appearing only with action) and 4
(persistent dystonia at rest). Truncal and limb movements
are assigned a weight of 0.5 and cranial movements are
assigned a weight of 1.0 for a maximal total score of 120.
In addition, there is a separate disability scale for activities
of daily life (speech, handwriting, feeding, eating/swal-
lowing, hygiene, dressing, walking) rated from 1 (normal)
to 4 (complete disability).
In 1997, a consensus conference of dystonia experts
developed the Unified Dystonia Rating Scale (UDRS) as a
simple tool to evaluate the severity of different forms of focal
dystonia (Comella et al. 2003). The UDRS includes two
components, a duration factor and a motor severity factor for
14 regions of the body. The duration factor is a 9-point scale
with 0.5 steps from 0 to 4. Similar to the Fahn–Marsden
dystonia scale, only one item of the UDRS severity scale
applies to CD (i.e. neck). Severity of movements is rated on
the following 5-point scale: 0 = none, 1 = mild (B25 % of
possible normal range), 2 = moderate ([25 % but B50 %
of possible normal range), 3 = severe ([50 % but B75 % of
possible normal range), 4 = extreme ([75 % of possible
normal range). Although applicable for generalized dysto-
nia, neither the Fahn–Marsden scale nor the UDRS is con-
sidered specific for CD.
Fahn (1989) worked on a rating scale particularly
designed for the assessment of CD resulting in the Columbia
Torticollis Rating Scale. This composite scale consists of
ratings for head movements (torticollis rating) and disability
scales. The torticollis scale documents the direction of
movement, the circumstances when the head deviation is
present, the duration of deviation while sitting, the range of
active movement, the excursion amplitude, the duration and
severity of pain while sitting, the degree of reduction in
deviation with the use of sensory tricks, the average fre-
quency, duration and severity of forceful spasms, the pres-
ence of tremor and gross jerking movements of the head, and
the presence of essential tremor of the hands. The disability
scale assesses the limitation of functional activities such as
driving, reading, watching television, going out to movies,
shopping, walking about, feeding, falling asleep, and per-
formance of housework or outside work. The value of this
detailed scale for descriptive clinical assessment was dem-
onstrated in a study defining the clinical characteristics of a
large cohort of CD patients (Chan et al. 1991). However, the
complexity might have prevented broad use in clinical
practice, and the utility for clinical trials remains unclear as it
was only applied in one double-blind, controlled trial
(Table 1, Greene et al. 1990).
Also in the 1980s, a comparably brief rating scale for CD
was developed by Tsui et al. (1985, 1986, 1987) and Stell
et al. 1988). It is an impairment scale which evaluates the
amplitude and duration of sustained posture and intermittent
movements of the head, as well as the presence of shoulder
elevation and tremor. Rotation, tilt, and sagittal movements
are rated on a 0–3 scale for a maximum of 9. Additionally,
head tremor is rated from 0 to 2 and shoulder elevation from 0
to 3. Multiplication by a duration score is performed for
amplitude of sustained movements (1 = intermittent,
2 = constant) and for tremor (1 = occasional, 2 = contin-
uous) resulting in a total possible score of 25. Poewe et al.
(1998) suggested a modification of the Tsui score to increase
the sensitivity of the scale for postural head deviations. Four
different modes of postural activation were performed to
assess the amplitude of sustained movements (sitting, lying,
standing, walking).
Another brief scale has been described by the research
group of Lang et al. specifically for the assessment of CD
(Weiner and Lang 1989). The degrees of turn (chin to side of
turn) plus degrees of tilt (ear down toward shoulder) are rated
in steps of 15 on a scale from 0 to 6, and sagittal movements
(anterocollis or retrocollis) are rated from 0 to 3. These are
added for a maximal score of 15 and multiplied by a severity
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Table 1 Use of rating scales in pivotal clinical studies with BoNT treatment for cervical dystonia (studies listed in chronological order)
References Study design BoNT Number
of CD
patients










55 GIR (?3 = markedly improved,
-2 = definitely worse); VAS for
functional capacity and for pain;
degree of head turning; Columbia
Torticollis Rating Scale
BoNT-A significantly improved the
severity of CD, disability, pain












Pain; Tsui score; HRQoL scale
TWSTRS-Disability (primary
outcome), Tsui score and HRQoL












122 TWSTRS-Total score; subscores for
severity, disability and pain; VAS
for pain; VAS for investigator and
patient global assessment of
change; Sickness Impact Profile
scores
TWSTRS-Total score (primary
outcome) improved for all
treatment groups (including
placebo), but BoNT-B was
significantly superior.
Improvement with BoNT









75 Tsui score (modified version); pain
on 4-point scale; global
assessment of improvement post
injection; global rating of efficacy;
need for retreatment at week 8
Magnitude of improvement was
greatest after 1,000 U BoNT-A,
but with significantly more AEs;











77 TWSTRS-Total score; subscores for
severity, disability and pain; VAS
for pain; VAS for investigator and
patient global assessment of
change
Significant difference in favor of
BoNT-B for primary (TWSTRS-











109 TWSTRS-Total score; subscores for
severity, disability and pain; VAS
for pain; investigator and patient
global assessment of change
The mean improvement in
TWSTRS-Total score (primary
outcome) was significantly in
favor of BoNT-B, but higher for










80 TWSTRS-Total score; subscores for
severity, disability and pain; VAS
for pain
Improvement in TWSTRS-Total
score was the result of
improvement in each of the three
subscale scores. BoNT-A
improved not only head position













VAS for pain; 9-point Global
Response Scale; responder rates;
investigator global assessment of
efficacy
Improvement in TWSTRS-Severity
score (primary outcome) 4 weeks












111 TWSTRS-Total score; subscores for
severity, disability and pain; VAS
for pain; investigator and patient
global assessment
Improvement in TWSTRS-Total
score (primary outcome) 4 weeks
after BoNT-B was non-inferior to
BoNT-A
AEs adverse events; BoNT botulinum neurotoxin; GIR Global Improvement Rating; HRQoL health-related quality of life; TWSTRS Toronto
Western Spasmodic Torticollis Rating Scale; U units; VAS Visual Analogue Scale
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factor (0 = none to 4 = severe) leading to a maximum sum
score of 60. In addition, the time to a maximum of 60 s that
the patient is able to hold the head fixed in the central position
is also measured. This scale was subsequently altered and
expanded to form the Toronto Western Spasmodic Torti-
collis Rating Scale (TWSTRS) Severity scale described
below.
The TWSTRS is a composite scale which covers different
features of CD (Consky et al. 1990; Consky and Lang 1994;
Comella et al. 1992; Dubinsky et al. 1991). The first part is based
on the physical findings (severity subscale), the second part rates
disability, and the third part pain. Details of the TWSTRS are
displayed on the Web site http://www.wemove.org. The
TWSTRS-Severity scale includes the following items: A. max-
imal excursion (rotation, tilt, anterocollis or retrocollis, lateral
shift, sagittal shift), B. duration factor, C. effect of sensory tricks,
D. shoulder elevation/anterior displacement, E. range of motion
(without the aid of sensory tricks), F. time (up to 60 s that the
patient is able to maintain the head within 10 of the neutral
position without the use of sensory tricks). The sum of A to F
amounts to a maximum score of 35 with the duration factor
weighted twice.
The TWSTRS-Disability is a six-item scale that com-
prises an assessment of performances of daily activities
which may be possibly affected by CD: work performance
(job or domestic), activities of daily living (feeding,
dressing, hygiene), driving, reading, watching television,
and leisure activities outside the home. Each item is rated
on a 6-point scale (0 = no difficulty, 5 = highest degree of
disability). The TWSTRS-Pain consists of a severity score
for the patient’s usual, worst, and best pain in the last week,
as well as a duration component and an assessment of the
contribution of pain to disability. The score range is
between 0 and 20, with 20 assigned to the highest possible
experienced pain.
In addition to rating scales assessing the functional
impairment due to CD, some research groups have made
attempts to implement instruments for quantification of
health-related quality of life (HRQoL) (Cano et al. 2004b;
Slawek et al. 2007). HRQoL instruments should on the one
hand be relevant to patients and on the other hand sensitive
enough to assess functional health and treatment effects in
clinical trials and in daily practice. The aim was to develop
a disease-specific questionnaire that addresses the percep-
tions and concerns of patients with CD. Cano et al. (2004a,
2006) created a 58-item rating scale (CD Impact Profile,
CDIP-58) measuring the health impact of CD in eight areas
(head and neck symptoms, pain and discomfort, activities,
walking, sleep, annoyance, mood, and psychosocial func-
tioning). The research of the Austrian Botulinum Toxin and
Dystonia Study Group (Mu¨ller et al. 2004) resulted in a
shorter, 24-item questionnaire (CDQ-24) based on 5 sub-
scales: stigma, emotional well-being, pain, activities of
daily living, and social/family life. Each item is scored
from 0 (never) to 4 (always), representing increasing
severity of impairment. HRQoL questionnaires can be used
in combination with clinical rating scales of dystonia
severity to capture the status of patient’s well-being.
Validation of rating scales for CD
The Fahn–Marsden rating scale for generalized dystonia
has been validated by assessment of videotapes (Burke
et al. 1985). In this evaluation, 10 patients were rated on a
simple global scale from 0 to 5 and in parallel by the Fahn–
Marsden rating scale. All patients were rated twice by two
assessors. A close correlation (r = 0.9) was found between
different raters and an almost 100 % correlation between
repeated ratings, demonstrating good inter-rater and intra-
rater reliabilities. In a validation study with 25 dystonia
experts, the UDRS showed a very good correlation with the
Fahn–Marsden dystonia scale. Inter-rater agreement was
fair to excellent with intraclass correlation coefficients
ranging from 0.71 to 0.78 (Comella et al. 2003). The
modifying ratings (duration of the UDRS and provoking
factor in the Fahn–Marsden scale) showed less agreement
than the motor severity ratings. Neither the Fahn–Marsden
scale nor the UDRS have been tested for clinical respon-
siveness to therapeutic interventions or reproducibility
(Jankovic and Tolosa 2007).
There are a couple of publications about the reliability of
rating scales specific for CD. The inter-observer variability
of the Tsui score was determined by means of randomized
videotape recordings which were again scored ‘‘blind’’ by
another physician (Tsui et al. 1986). The inter-observer
correlation (0.86–0.87) showed that the scale gives repro-
ducible results (Tarsy 1997). However, scatter between rater
scores for any individual patient has been high (Gelb et al.
1989; Moore and Blumhardt 1991). Furthermore, in some
studies, there have been major differences between scores
and patient’s subjective assessments of therapeutic response
(Gelb et al. 1989; Blackie and Lees 1990). The Cervical
Dystonia Severity Scale, which is very similar to the Tsui
score, was evaluated in 42 patients with CD rated by two
different assessors at each of four participating centers twice
in the same day. The scale was very reproducible within and
between different raters, with correlations ranging from 0.79
to 0.94 (O’Brien et al. 2001).
The TWSTRS is a validated scale which has been fre-
quently applied in clinical trials as the primary outcome
parameter. A total of 200 CD patients were videotaped by
using the TWSTRS videotape protocol and independently
assessed by three movement disorder specialists. The panel
rated the videotape segments of the individual subsections of
the TWSTRS and subsequently, the full patient cases
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(Comella et al. 1997). The rates of agreement for all indi-
vidual components of the TWSTRS and the total TWSTRS
were statistically significant (all p \ 0.01). The inter-rater
agreement was highest for rotation, anterocollis, and retro-
collis and lowest for lateral shift. In addition, a substantial
correlation could be demonstrated for the change in
TWSTRS-Severity score after BoNT treatment and patient
perception of overall improvement as well as for the change
in disability and pain scores (Consky et al. 1990; Consky and
Lang 1994).
The validity and reliability of the disease-specific
HRQoL questionnaire CDQ-24 were determined in 231
patients with cranial and cervical dystonia. The evaluation
also included the Short Form-36 Health Survey (SF-36) as
a general HRQoL instrument, the Tsui score to assess
severity of CD, and a global assessment of pain (Mu¨ller
et al. 2004). High correlations were found between those
CDQ-24 and SF-36 subscales that measure similar aspects.
Patients with CD showed low correlations of the CDQ-24
subscores with the Tsui score, which could be expected as
the Tsui score rates functional impairment and does not
include HRQoL. However, correlations of CDQ-24 sub-
scores with pain ratings were higher. The CDQ-24 ques-
tionnaire showed good reliability properties and appears to
be sensitive to changes that are important to patients.
Use of rating scales for CD in clinical studies
with botulinum toxin
Of the approximately 80 studies with BoNT in CD which
have been published, 14 are controlled studies (Kamm and
Benecke 2011). Of these seven randomized, double-blind
studies were classified as class I evidence by the AAN, four
studies with BoNT-A and three studies with BoNT-B
(Simpson et al. 2008). For the tabulated overview (Table 1),
another double-blind class I study comparing BoNT-A and
BoNT-B (Pappert and Germanson 2008; Kamm and
Benecke 2011) and the comparator-controlled study of
Benecke et al. 2005 (class II), which was pivotal for the
marketing authorization of Xeomin, were incorporated.
Five of the pivotal studies compiled in Table 1 used the
TWSTRS-Total score as the primary outcome parameter
(Lew et al. 1997; Brin et al. 1999; Brashear et al. 1999; Truong
et al. 2005; Pappert and Germanson 2008). Only in one of
these studies, the Tsui score was applied as primary outcome
(Poewe et al. 1998). Nevertheless, in the 1980s and 1990s, the
Tsui score was implemented in several other controlled
studies to assess the treatment effect of BoNT (Kamm and
Benecke 2011). A couple of studies only applied a TWSTRS
subscore as the primary efficacy parameter, e.g. the TWSTRS-
Severity score in the study of Benecke et al. 2005. The
TWSTRS-Disability was the primary outcome in the study of
Brans et al. (1996), whereas TWSTRS-Pain and Tsui score
were used, in addition, as secondary parameters. Greene et al.
(1990) conducted the only study which employed the
Columbia Torticollis Rating Scale. However, the report of the
study does not present the outcome for the total score, but
describes the response to BoNT injections primarily by a
patient-based Global Improvement Rating (GIR) from ?3
(markedly improved) to -2 (definitely worse).
There are a few studies applying several different rating
scales in order to determine which is the most suitable to
evaluate treatment effects of BoNT in patients with CD.
Tarsy (1997) assessed 76 consecutive idiopathic CD
patients with both Tsui score and TWSTRS before and
after injection of BoNT. Tsui and TWSTRS-Total score
reduction rates after treatment correlated significantly
(Pearson correlation coefficients 0.57;\0.0001). Also Tsui
and TWSTRS-Severity, which are both objective ratings of
clinical severity, showed a comparable high correlation. In
contrast, there was only weak or no correlation of
TWSTRS-Pain score reduction with either of the objective
severity scales. Based on these results, the author suggests
that an objective scale of severity such as either the Tsui
score or the TWSTRS severity subscale in conjunction
with the TWSTRS pain subscale adequately assesses the
improvement of CD following treatment with BoNT.
Odergren et al. (1994) come to a similar conclusion and
recommend using a combination of Tsui score for dystonic
posture and movement ability and a Visual Analogue Scale
(VAS) for pain to assess the efficacy of BoNT. In accor-
dance with the results of Tarsy (1997) described above,
another study in 64 CD patients receiving BoNT injections
demonstrated a poor correlation between motor findings
from the Tsui score and pain and disability sections of the
TWSTRS (Lindeboom et al. 1998). In this study, there
were no differences between the effect sizes of impairment
and pain of patients who continued treatment and drop-
outs. This suggests that these outcome measures do not
appropriately reflect BoNT efficacy. The authors conclude
that disability, handicap and a global measure of disease
burden were the most suitable outcome parameters to
determine the clinical efficacy of BoNT.
Assessment of rating scales for CD
The efficacy of BoNT in idiopathic CD has been evaluated
in a huge number of clinical studies, but there is still no
final clue which is the optimal rating scale to assess
treatment effects. This section will provide a thorough
appraisal of the advantages and drawbacks of Tsui score,
TWSTRS, and UDRS, which are the most current rating
scales used in clinical studies as well as in daily clinical
practice.
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The UDRS is a simple, validated rating scale for gen-
eralized assessment of focal dystonia and comprises dura-
tion as well as a severity factor. The duration rating of the
UDRS parallels the duration factor of the TWSTRS. The
severity of abnormal movements can be uniformly descri-
bed in steps of 25 % for dystonia in different regions of the
body. An obvious advantage of the UDRS is that the scale
can be easily implemented across multicenter studies with
many investigators and in daily practice to evaluate
patients with different forms of focal dystonia.
The main drawback for the assessment of CD is that the
UDRS includes only one item for CD (i.e. neck) and is,
therefore, not precise enough to describe disease-specific
features. Severity is rated from 0 to 4 in steps of 25 %, but
there is no definition which degree of excursion corre-
sponds to each of the numerical ratings. Furthermore, the
UDRS does not include ratings for pain and disability, i.e.
factors that are important to patients. The effect of sensory
tricks is not covered, and the scale does not take into
account if the patient is able to change the dystonic posture.
Altogether, the UDRS is not an adequate tool to assess the
complex clinical picture of CD neither in daily practice nor
in clinical trials.
The scoring system developed by Tsui comprises a
rating for sustained movement amplitudes, duration,
shoulder elevation and, in addition, for dystonic tremor.
The Tsui score is a brief and relatively simple rating scale
specific for CD which can easily be implemented in daily
clinical routine. However, due to its simplicity, several
features of CD regarded as relevant by patients are not
covered, e.g. the scale does not include a rating for pain,
disability, and HRQoL. In consequence, it shows only low
correlation with HRQoL scales, which might be the
explanation that in some studies there have been major
differences between Tsui score and patient’s subjective
assessments of therapeutic response. A deficiency for the
use in multicenter studies by different investigators is
the lack of a precise definition under which conditions the
assessment should be carried out (e.g. sitting, eyes closed
etc.). Different modes of postural activation (sitting, lying,
standing, walking) can thus lead to diverging results. For
the sake of reliability, it is essential that all potential
assessors have the same understanding of each single item
of a rating scale. The Tsui score uses the designations
‘‘mild’’, ‘‘moderate’’, and ‘‘severe’’ for some ordinal scores
(e.g. for anterocollis and retrocollis) but a clear criterion
definition for these ratings is missing.
Another immanent disadvantage of this scale lies in the
fact that mixed forms of CD are generally assigned higher
scores than simple forms, and thus, the sum score does not
provide an appropriate measure of the extent of impair-
ment. The Tsui score does not comprise a separate item for
shift. In consequence, shift is underestimated in the total
score as the degree of head deviation is minor compared to
torticollis or laterocollis. Consky and Lang (1994) raised
the point that measurements of sustained movement
amplitudes are extremely difficult because maximal
excursions may be sustained for only a short duration, and
submaximal deviations may be otherwise constantly evi-
dent. Considering this fact, the simple dichotomous rating
of 1 (intermittent) and 2 (constant) is not precise enough to
describe the duration of sustained movements. It is also
unclear if the evaluation of duration should only be based
on the observation of the assessor or should also take into
account the information provided by patients.
Further drawbacks of the Tsui score are that the scale
does not include the effect of sensory tricks and that it
captures only the abnormal posture but not the interaction
of voluntary movements, whereas the TWSTRS includes a
question if the patient is able to move the head toward or
past midline. As an advantage compared to the TWSTRS,
the Tsui score covers the assessment of dystonic tremor.
But the rating of ‘‘continuous’’ for duration of tremor is
questionable because the majority of the patients will not
confirm that the tremor is present all the time without any
interruption. The rating for tremor is also problematic from
the statistical point of view. When multiplying tremor
severity by duration, a result of 3 is not possible. The
assumption of a Gaussian distribution cannot be made for
statistical tests if values are missing within a score.
The TWSTRS covers the functional features of CD
(severity subscale) as well as the aspects which are
important to patients (disability and pain subscales).
A positive correlation was demonstrated between change in
severity score rated by physicians and patient’s self-
reported improvement in disability and pain after treatment
with BoNT (Consky et al. 1990). The TWSTRS is a vali-
dated scale including a videotape protocol such that
patients are viewed in a standardized fashion. This ensures
consistency and reproducibility across raters for multicen-
ter trials. The TWSTRS videotape protocol is a valuable
tool for a standardized assessment in clinical trials but
might be too complex to be applicable in routine clinical
practice. Similar to the Tsui score, the TWSTRS-Severity
combines the amplitude of movements with a duration
factor. In contrast to the dichotomous rating of duration
(1 = intermittent, 2 = constant) of the Tsui score, the
TWSTRS duration factor provides a more sophisticated
assessment of duration on a 6-point scale in 25 % steps
taking into account the proportion of time that the head
deviation is most often maximal or submaximal in ampli-
tude. Furthermore, the TWSTRS-Severity includes an item
for the effect of sensory tricks.
Despite the obvious advantages of the TWSTRS, there are
also some points of constructive criticism to be considered
for the development of future scales. As already mentioned
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above, the TWSTRS does not enable to evaluate dystonic
tremor; however, from the experience with the Tsui score,
the difficulties to define a rating for tremor are evident. In
addition, there is no scientific evidence to support the fact
that rating of duration is weighted twice. The effect of tricks
is rated from 0 (complete relief by one or more tricks) to 2
(little or no benefit from tricks). At bottom, a rating of 2 for
the missing effect of tricks is not a measure of severity, and
the fact that a patient who does not benefit from tricks does
not have any impact on therapeutic decisions, but it is
assigned the same weight, as for a moderate laterocollis. On
the other hand, subtypes of CD which can be extremely
disabling for the patient tend to be underestimated. Antero-
collis can be assigned a maximum rating of 3—severe in case
the chin approximates the chest because no other items (turn,
tilt or shift) are applicable. Furthermore, items A. ‘‘Maximal
excursion’’ and E. ‘‘Range of motion’’ of the TWSTRS-
Severity scale basically describe the same aspects of
abnormal posture, i.e. the ratings for these items are not
independent from each other. Comella et al. (1997) raised
some scale deficiencies already quite soon after the imple-
mentation of the TWSTRS. The author pointed out that there
is no explicit definition of midline and full range for
assessment of each of the three axes of movements.
Tsui score as well as TWSTRS has been used in
numerous clinical studies and despite some drawbacks, as
described above, proved their value to assess treatment
effects of BoNT for decades. Although both rating scales
are specific for CD, they are not able to cover all aspects of
the disorder. Moreover, the phenomenological classifica-
tion of CD has recently undergone a revision which chal-
lenges the accuracy of current rating scales. Are the rating
scales for CD which are employed at present still valid to
measure what they were originally designed to measure?
The goal of the investigation of Reichel (2011) in 78
patients with CD was to avoid primary non-responders to
BoNT treatment and to inject those muscles that are
causally involved in the pathology of the respective sub-
types of dystonia. The author came to the conclusion that it
is necessary to distinguish between neck and head types of
CD (-collis and -caput) because different groups of muscles
are affected. It was shown that in 20 % of the patients, the
abnormal movement and/or posture only involves muscles
which work on the atlanto-occipital joints (latero-, antero-,
retro- or torticaput), and in further 20 %, it only affected
muscles in the region of the cervical spine (latero-, antero-,
retro- or torticollis). Sixty percent of the patients exhibited
both head and neck types of CD but with a different degree
of ‘‘caput’’ and ‘‘collis’’ involvement. Neither Tsui score
nor TWSTRS-Severity allows a differentiation between
-collis and -caput types of CD and, in consequence, need to
be reworked to match the new phenomenological
classification.
Discussion and conclusions
Assessment of treatment outcome in clinical studies and in
daily practice is only as reliable and valid as the instrument
applied. Proper evaluation of patients with CD is a crucial
point because clinical decisions and results of clinical
studies are mainly dependent on the scientific quality of the
rating scales employed. Although technical aids have been
developed such as Zerviton, a helmet system with cus-
tom-built software to measure dystonic postures of the
head, these are not established in routine practice (Sommer
et al. 2009). Treatment protocols for BoNT still differ
considerably with regard to dose, injected muscles and
number of injection sites. Progress in defining the most
effective treatment approach and in ensuring comparability
of results across several clinical studies significantly
depends on the consensus about an appropriate rating scale
which can be accepted as a standard throughout the sci-
entific community.
Regardless of the rating scale applied, there are some
inherent difficulties of measuring the severity of CD due to
its variability depending on emotional stress, fatigue or
activity. A rating scale for CD has to encompass the het-
erogeneity and variability of the clinical features of the
disorder. It should include not only an assessment of the
extent of dystonic movements but also for pain, disability,
and quality of life, i.e. aspects which are most relevant to
patients. None of the current rating scales reviewed above
provides the possibility to rate all these complex aspects of
the disorder.
The Scientific Advisory Group of the Medical Outcomes
Trust (SAC 2002) recommended criteria for health mea-
surement rating scales which represent the most current and
complete guidelines. The SAC defined a set of eight key
attributes for rating scales: conceptual and measurement
model, reliability, validity, responsiveness, interpretability,
respondent and administrative burden, alternate forms, and
cultural and language adaptations. At a minimum, the eval-
uation of a rating scale should include reliability (the extent
to which an instrument yields reproducible results), validity
(the extent to which an instrument measures what it is
designed to measure), and responsiveness (the extent to
which a scale is responsive to detect a significant change in
clinical status over time) (Consky and Lang 1994; Cano et al.
2004b). Furthermore, it is important that the content of a
rating scale for CD is based on the actual conceptual disease
model, e.g. the most current classification of CD, as well as
empirically derived aspects from clinical practice. Finally,
practical issues, such as the time taken to complete the scale,
interpretability and considerations of patient burden are also
relevant factors (SAC 2002; Cano et al. 2004b).
As illustrated in Table 2, the available CD-specific rat-
ing scales have not been developed strictly according to the
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guidelines described above. None of them cover at least the
three essential criteria recommended by the Medical Out-
comes Trust (reliability, validity, and responsiveness).
Although Tsui score and TWSTRS have been widely used
as primary outcome parameter in clinical studies, they have
not been rigorously tested for responsiveness. Table 3
summarizes the pros and cons for Tsui score and TWSTRS
which are the most frequently employed rating scales for
CD in clinical practice as well as in clinical trials. An
important drawback is that neither Tsui score nor TWSTRS
reflects the most current conceptual model of CD. In a
previous publication, Reichel (2011) describes a new
classification for CD and points out the clinical importance
to differentiate between head and neck subtypes. In con-
sequence, there is an obvious deficiency to exactly describe
all subtypes of CD with the rating scales available at
present, and the need to develop a rating scale which
includes the possibility to distinguish between ‘‘-collis’’
and ‘‘-caput’’ subtypes of CD.
As a first step to come to a consensus for an improved
rating scale for CD, the authors collected their thoughts to
the requirements for an ‘‘ideal’’ rating scale. A rating scale
has to be easy to understand, easy to handle, and swiftly to
apply. It must be reproducible if used by different raters
and applicable in daily clinical routine as well as in clinical
studies. Symptoms of the disorder should be rated by an
ordinal numeric score, e.g. from 0 to 4 with increasing
symptom severity. The aim of the scale is to cover all
relevant symptoms of the target disease including those
which are important to characterize the disorder but do not
respond well to current treatment options. The same
numeric scores should be used for each item of the rating
scale. Particularly, the approach will be to assign the same
weight to each item of the scale, although this might not be
achievable for all items. At least, the attempt will be made
that none of the symptoms are overrated or underestimated.
Based on these assumptions, it should be possible to use the
scores for statistical calculations.
The absolute sum score should provide a clear measure
of the severity of the disease, the higher the value, the more
the patient is affected. Accordingly, a reduction in score
should closely correlate with therapeutic improvement.
A rating scale has to be applicable for different therapeutic
approaches and be sensitive enough to discriminate
between less or more effective treatments. From the cli-
nician’s perspective, it would be preferable that rating
results could serve as guidance for selection of therapeutic
algorithms and BoNT injection schemes. Furthermore,
some components of the scale should be applicable to
assess patient’s perspective of the disorder or even HQoL.
Most likely, a rating scale for CD will comprise several
subscales to cover symptom severity, impact on patient’s
daily activities, and social burden of the disease.
Currently, we face the situation that none of the rating
scales most frequently used in clinical practice offer the
possibility to take a new classification of CD into account.
A future rating scale should be designed to be independent
of potential scientific findings which could change the
diagnosis or classification of the target disease. These
preliminary suggestions for the design of a standardized
rating for CD represent only a first approach which needs
to be further worked out with a panel of experts. During the
development and validation process of the rating scale, it
will turn out how many of the above-mentioned require-
ments can be put into practice or will remain wishful
thinking.
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Table 2 Evaluation of rating scales according to the Medical Out-
comes Trust criteria
Rating scales Criteria fulfilled
Reliability Validity Responsiveness










Modified from Cano et al. (2004b)





Brief and easy to apply Yes No
Standardized videotape protocol No Yes
Rating for amplitude of movements Yes Yes
Duration factor Yes Yes
Rating for shoulder elevation Yes Yes
Rating for shift No Yes
Rating for tremor Yes No
Effect of sensory tricks No Yes
Disability scale No Yes
Pain scale No Yes
Differentiation between -collis and -caput
types of CD
No No
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